PHILADELPHIA , Aug. 26, 2025 /PRNewswire/ -- Berger Montague PC is investigating potential securities fraud claims on behalf of investors in RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST) .

RxSight, headquartered in Aliso Viejo, CA , is a medical technology company that develops light adjustable intraocular lenses (LAL) used in cataract surgery. Its RxSight system involves the Company's Light Delivery Device (LDD).

On July 8, 2025 , RxSight revealed significant declines in LDD sales, LAL utilization, and overall revenue in Q2 2025, also lowering its full-year 2025 revenue guidance. CEO Ronald Kurtz disclosed at that time that "[a]doption challenges over the last few quarters have been a primary reason for the LDD stall."

On this news, RxSight shares fell $4.84 , or 37%, to a

See Full Page